Oak Harbor Wealth Partners LLC Sells 101 Shares of Amgen Inc. (NASDAQ:AMGN)

Oak Harbor Wealth Partners LLC cut its position in Amgen Inc. (NASDAQ:AMGN) by 6.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,392 shares of the medical research company’s stock after selling 101 shares during the period. Oak Harbor Wealth Partners LLC’s holdings in Amgen were worth $363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Swedbank AB lifted its holdings in Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after buying an additional 5,751 shares in the last quarter. Graypoint LLC grew its position in shares of Amgen by 3.0% in the 3rd quarter. Graypoint LLC now owns 5,164 shares of the medical research company’s stock worth $1,664,000 after buying an additional 148 shares during the last quarter. Cozad Asset Management Inc. grew its position in Amgen by 3.7% during the 3rd quarter. Cozad Asset Management Inc. now owns 1,695 shares of the medical research company’s stock worth $546,000 after purchasing an additional 60 shares during the last quarter. Principal Financial Group Inc. grew its position in Amgen by 6.0% during the 3rd quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company’s stock worth $204,659,000 after purchasing an additional 35,785 shares during the last quarter. Finally, Western Pacific Wealth Management LP grew its position in Amgen by 245.2% during the 3rd quarter. Western Pacific Wealth Management LP now owns 535 shares of the medical research company’s stock worth $172,000 after purchasing an additional 380 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several research reports. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Wolfe Research initiated coverage on shares of Amgen in a research report on Friday, November 15th. They set a “peer perform” rating for the company. William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Citigroup reissued a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $314.95.

Amgen Stock Up 2.2 %

Shares of NASDAQ:AMGN opened at $324.86 on Friday. The stock has a market cap of $174.52 billion, a price-to-earnings ratio of 43.03, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm’s 50 day moving average price is $286.14 and its 200 day moving average price is $299.89.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 2.93%. Amgen’s dividend payout ratio (DPR) is 126.09%.

Insiders Place Their Bets

In related news, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 69,341 shares of company stock worth $20,644,335. Corporate insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.